Get started
INCYTEINCYTEINCYTE

INCYTE

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

4INCY trade ideas

INCYTE CORPORATION (INCY)Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve acute and chronic GVHD, as well as Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC); and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome, as well as a pivotal program for solid tumors with driver activations of FGF/FGFR. Further, it is involved in developing INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Additionally, the company develops Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Syros Pharmaceuticals, Inc.; and Innovent Biologics, Inc., as well as BriaCell Therapeutics Corp. for treating cancer. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
NASDAQ:INCYLong
by fonsecadr
1
Long or short INCYTE corp ? Move coming soon. Fundamentally nothing much has changed in INCY recently but technically the stock is reaching a point of decision, is the correction? can we go higher? we are biased towards a break higher as indicators are improving while the price gets squeezed between they 100 and 200ma. The $82 region may be a good area to look for a long on a break from converging trendlines, while also clearing the MA's resistance, a bounce of the bottom Bollinger Band is also anticipated. AVERAGE ANALYSTS PRICE TARGET $87 AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT COMPANY PROFILE Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
NASDAQ:INCY
by RedHotStocks
Good Short Idea!!Hey guys, I've been posting a lot of Bullish ideas recently, however due to the market instability, negative fundamentals, and recent failure to move past a key resistance point for the Indices, I've decided to post a short idea I know I could very possibly use myself if the market proves to be bearish. This stock, INCY, is ridiculously horrible. It's truthfully an $8 stock disguised as $80. It's hard terrible luck in it's past and now is far from any different. Even excluding negative EV/EBITDA and terrible EPS numbers, this is still a fantastic technical setup. Stock has super bearish 30-minute and Daily charts, 5 Day MA seems to be moving down and it's formed a nice downward channel. Profit targets are around $80 (Super conservative), $76.5(Moderate), and $70 (Aggressive). Depends on time-frame of stock, shouldn't take that long of a move, maybe 2 weeks at most. Another profit target would be when the daily RSI hits around 25-28, seems to be a support point. Just figured I'd post this. Remember never to short a stock in a positive, up-trending market, and never go long a stock in a negative, down-trending market. Why take the risk of going against the market when it pays off more to follow the market and increase your risk due to the certainty of the market trend? Leave questions down below.
NASDAQ:INCYShort
by croganm
INCY: sold ahead of earnings, looking 4 re-entry after reassessmNot sure if the BLUE support is gonna hold this time around. Might eventually sets on ~9yr-old support (note chart is in Log scale). Monthly chart also showing massive MACD divergence. As a result, sold my position to see how is gonna play out in the ST. Also binary outcome drug data expected this year, with unknown timing. However, INCY is top pick at Credit Suisse and has bear case scenarios (considering other banks too) in the $65-70 range. But the massive MACD divergence on the monthly (although not showing up on the weekly..uhm?) + very long bull run made me reconsider the position I opened at $94.5 a couple of weeks ago, so I'll just sit aside for the time being. The thing is, where's there risk, there is opportunity: I am cognizant that by sitting aside I might be missing out on some upside here. I'll wait for a reversal of the downtrend to jump on, obv missing out on the first bit (provided it doesn't coincide with a spike up 100% any positive drug data released later in the yr).
NASDAQ:INCY
by prossi